Traws Pharma Files 10-K/A Amendment for Part III Info
Ticker: TRAW · Form: 10-K/A · Filed: Apr 30, 2025 · CIK: 1130598
| Field | Detail |
|---|---|
| Company | Traws Pharma, Inc. (TRAW) |
| Form Type | 10-K/A |
| Filed Date | Apr 30, 2025 |
| Risk Level | low |
| Sentiment | neutral |
Sentiment: neutral
Topics: amendment, 10-K, filing-update
TL;DR
Traws Pharma finally dropped the rest of its 2024 10-K, including the juicy Part III details.
AI Summary
Traws Pharma, Inc. filed an Amendment No. 1 on Form 10-K/A to its Annual Report for the fiscal year ended December 31, 2024. This amendment, filed on April 30, 2025, includes information required by Part III of Form 10-K, which was initially omitted pending the filing of its definitive proxy statement.
Why It Matters
This filing provides crucial Part III information for Traws Pharma's 2024 annual report, which is necessary for investors to have a complete picture of the company's governance and executive compensation.
Risk Assessment
Risk Level: low — This is an amendment to a previously filed 10-K to include missing Part III information, not a new filing with material changes.
Key Numbers
- 2024 — Fiscal Year End (The annual report covers the fiscal year ending December 31, 2024.)
- 10-K/A — Filing Type (This is an amendment to the annual report.)
Key Players & Entities
- Traws Pharma, Inc. (company) — Filer of the 10-K/A
- December 31, 2024 (date) — Fiscal year end for the reported period
- March 31, 2025 (date) — Original filing date of the Form 10-K
- April 30, 2025 (date) — Filing date of this Amendment No. 1 on Form 10-K/A
- Onconova Therapeutics, Inc. (company) — Former company name
FAQ
What specific information is being added in Part III of this 10-K/A amendment?
The filing states that Part III information, previously omitted, is now being included. This typically covers executive compensation, related party transactions, and principal accounting fees and services.
Why was the Part III information initially omitted from the Original Form 10-K filed on March 31, 2025?
The Part III information was omitted in reliance on General Instruction G(3) to Form 10-K, which allows incorporation by reference from the definitive proxy statement if filed no later than 120 days after the fiscal year-end.
What is the deadline for filing the definitive proxy statement to avoid filing a 10-K amendment for Part III information?
The definitive proxy statement must be filed no later than 120 days after the company's fiscal year-end.
What was Traws Pharma's former company name?
Traws Pharma, Inc. was formerly known as Onconova Therapeutics, Inc.
What is the business address and phone number for Traws Pharma, Inc.?
The business address is 12 Penns Trail, Newtown, PA 18940, and the business phone number is 267-759-3680.
Filing Details
This Form 10-K/A (Form 10-K/A) was filed with the SEC on April 30, 2025 regarding Traws Pharma, Inc. (TRAW).